Biovail Corp. (BVF) filed Annual Report for the period ended 2010-12-31. Biovail Corp. has a market cap of $4.18 billion; its shares were traded at around $26.35 with a P/E ratio of 15 and P/S ratio of 5.1. The dividend yield of Biovail Corp. stocks is 1.4%.

except where the context otherwise requires, all references in this Annual Report on Form 10-K (“Form 10-K”) to the “Company”, “we”, “us”, “our” or similar words or phrases are to Valeant Pharmaceuticals International, inc. and its subsidiaries, taken together. in this Form 10-K, references to “$” and “US$” are to United States dollars and references to “C$” are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form 10-K are presented as of December 31, 2010.

On February 9, 2011, we acquired the Canadian rights to Cholestagel®, an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation for a $2.0 million upfront payment, to be followed by potential additional milestone payments totaling up to $7.0 million.

On November 1, 2010, we entered into two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV). under the terms of the first agreement, Valeant paid Kadmon Pharmaceuticals LLC (“Kadmon”) $7.5 million for exclusive rights to all Kadmon dosage forms of ribavirin, including 200 mg, 400 mg, and 600 mg tablets and capsules, in Poland, Hungary, the Czech Republic, Slovakia, Romania and Bulgaria. Valeant will source these products from Kadmon. under the terms of a second agreement, Valeant granted Kadmon an exclusive, worldwide license to taribavirin, excluding the territory of Japan, in exchange for an upfront payment of $5.0 million, other development milestones, and royalty payments in the range of 8-12% of future net sales. The fair value associated with taribavirin was included in the acquired in-process research and development (“IPR&D”) assets identified as of the Merger Date.

On June 2, 2010, we entered into a license agreement with Kyowa Hakko Kirin co., Ltd. (“Kyowa Hakko Kirin”) to acquire the U.S. and Canadian rights to develop and commercialize products containing istradefylline — a new chemical entity targeted for the treatment of Parkinson’s disease. under the terms of the license agreement, we paid an upfront fee of $10.0 million, and we could pay up to $20.0 million in potential development milestones through U.S. Food and Drug Administration (“FDA”) approval and up to an additional $35.0 million if certain sales-based milestones are met. We will also make tiered royalty payments of up to 30% on net commercial sales of products containing istradefylline. This acquisition was accounted for as a purchase of IPR&D assets with no alternative future use. accordingly, the $10.0 million upfront payment, together with $0.2 million of acquisition costs, was charged to acquired IPR&D expense in the second quarter of 2010. in connection with this acquisition, we also entered into an agreement with Kyowa Hakko Kirin for the supply of the istradefylline compound.

On March 25, 2010, we acquired certain AMPAKINE® compounds, including associated intellectual property, from Cortex Pharmaceuticals, inc. (“Cortex”) for use in the field of respiratory depression, a brain-mediated breathing disorder. This acquisition was accounted for as a purchase of IPR&D assets with no alternative future use. accordingly, the $9.0 million upfront payment and the $1.0 million transition payment made by us to Cortex, together with $0.7 million of acquisition costs, were charged to acquired IPR&D expense in the first quarter of 2010. As described below under “Products in Development”, we have suspended development of the AMPAKINE® compounds and are reviewing our options with Cortex.

On February 9, 2010, we entered into a collaboration and license agreement with Alexza Pharmaceuticals, inc. (“Alexza”) to acquire the U.S. and Canadian development and commercialization rights to AZ-004 for the treatment of psychiatric and/or neurological indications and the symptoms associated with these indications. This acquisition was accounted for as a purchase of IPR&D assets with no alternative future use. accordingly, the $40.0 million upfront payment made by us to Alexza, together with $0.3 million of acquisition costs, was charged to acquired IPR&D expense in the first quarter of 2010. As described below under “Products in Development”, by notice to Alexza dated October 18, 2010, we terminated our agreement with Alexza, effective January 16, 2011.

Read the The complete Report

Rate This Article:

Rating: 3.0/5 (1 vote)

8 November 2010 Last updated at 19:29 ET Share this page some 19 million people logged on for swine flu information

An NHS website which encourages people to self-diagnose saves the health service millions of pounds a year, a study suggests.

Last year there were more than 100 million visits the NHS Choices site, a 10% increase compared with 2009.

The site offers patients a quick reference guide to illnesses, symptoms, diagnosis and treatment.

A separate study from Imperial College London found 70% of patients used the internet to search for information.

‘Trusted information’

A third of these then decided there was no need to visit their GP.

Reductions in avoidable and unnecessary consultations among young people could amount to savings of about £44m per year, the university's report said.

The NHS Choices annual report found some 19 million people logged on to the site for information on swine flu, while overall there were on average 200,000 visits a day.

The site has space for patients to write comments about hospitals and GP surgeries, and more than 40,000 have been posted so far.

Health minister Simon Burns said: "every day we use the internet and technology to organise our lives, and increasingly when it comes to our health.

"for example, more and more people are taking the information they have found online with them when they consult their GP. It is important they can find accurate, trusted information from sources such as NHS Choices.

"It is vital that every penny spent on the NHS counts, and the Imperial College research shows that tools like NHS Choices can help deliver savings."

One of the nation’s most common forms of sexually transmitted diseases has fallen to its lowest level ever recorded, but there’s still improvement needed, according to a government report out Monday.

The report, part of the Centers for Disease Control and Prevention’s annual report card on sexually transmitted diseases (STDs), found that the gonorrhea rate in 2009 ? the most recent year for which figures are available ? was at its lowest level since 1941. the report also found that syphilis rates among women held steady after several years of increases. But the number of U.S. chlamydia cases was up 19% since 2006.

The CDC said that while overall the findings are encouraging, “there are large disparities in STD rates by race and age. some racial/ethnic minority groups have much higher STD rates than whites, and young African Americans are particularly hard-hit.”

Syphilis rates among young black men were about double the rate they were in 2005, the CDC found. Chlamydia rates reached a record high in 2009, which the CDC said probably represents increased testing for the disease.

Gonorrhea infections in 2009 dropped to about 111 cases per 100,000 population, down 10.5% from 2008. the 2009 rate, the third consecutive annual decline, was the lowest since 1941.

One test can screen for gonorrhea and chlamydia. in 2000, a quarter of women 25 and under were tested for chlamydia, compared with nearly half in 2009.

Once diagnosed, all three reportable STDs are easily treated with antibiotics, said Charlotte Kent, acting director of the CDC’s Division of STD Prevention. Although gonorrhea causes symptoms, chlamydia is likely not to, so testing is critical, she said.

“Undiagnosed chlamydia and gonorrhea are preventable causes of infertility,” Kent said.

The overall syphilis rate has risen every year since 2001, mostly in men but, more recently, in women. in 2009, there were 4.6 cases per 100,000 population, a 59% jump since 2005.

Jeanne Marrazzo, president of the American Sexually Transmitted Disease Association, called the syphilis rate “alarming.”

Rates of all three STDs are higher in blacks than whites, Kent noted. “We’ve seen some definite signs of progress, but we still see these disparities exist,” she said.

The 2009 syphilis rate in blacks was nine times that of whites; in 1999, the difference was 24 times higher.

“It’s not an issue of behavior,” Kent said, but one related to the fact that the three STDs are more common in blacks.